Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies

Annals of Oncology

Volumn 14, Issue 6, 2003, Pages 913-921

  Braybrooke, J P ^a   Boven, E ^b   Bates, N P ^a   Ruijter, R ^b   Dobbs, N ^a   Cheverton, P D ^c   Pinedo, H M ^b   Talbot, Denis ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Daiichi Pharmaceuticals UK Ltd   (United Kingdom)

Author keywords

Exatecan mesylate; Phase I; Topoisomerase inhibitor

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; EXATECAN; MITOMYCIN C; NITROSOUREA; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG RESPONSE; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; NEUTROPHIL; PATIENT CODING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

EID: 0038236663     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg243     Document Type: Article

References (35)

1. Wall M, Wani M, Cook C et al. Plant antitumour agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 94: 3888-3890.
2. Li LH, Fraser TJ, Olin EJ et al. Action of camptothecin on mammalian cells in culture. Cancer Res 1972; 32: 2643-2650.
3. Drewinko B, Freireich EJ, Gottlieb JA. Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 1974; 34: 747-750.
4. Gallo RC, Whang-Peng J, Adamson RH. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 1971; 46: 789-795.
5. Eng WK, Faucette L, Johnson RK et al. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988; 34: 755-760.
6. Jaxel C, Kohn KW, Wani MC et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 1989; 49: 1465-1469.
7. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48: 1722-1726.
8. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997; 8: 837-855.
9. Muggia FM, Creaven PJ, Hansen HH et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972; 56: 515-521.
10. Slichenmyer WJ, Rowinsky EK, Donehower RC et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85: 271-291.
11. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
12. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
13. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
14. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
15. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14: 56-61.
16. Ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997: 15: 2183-2189.
17. Bookman MA, Malmstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16: 3345-3352.
18. Mitsui I, Kumazawa E, Hirota Y et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 1995; 86: 776-782.
19. Takiguchi S, Kumazawa E, Shimazoe T et al. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Jpn J Cancer Res 1997; 88: 760-769.
20. Ishii M, Iwahana M, Mitsui I et al. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. Anticancer Drugs 2000; 11: 353-356.
21. Joto N, Ishii M, Minami M et al. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int J Cancer 1997; 72: 80-86.
22. Maliepaard M, van Gastelen MA, Tohgo A et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001; 7: 935-941.
23. Kumazawa E, Jimbo T, Ochi Y et al. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother Pharmacol 1998; 42: 210-220.
24. Vey N, Giles FJ, Kantarjian H et al. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia. Clin Cancer Res 2000; 6: 731-736.
25. Kajimura T. DX-8951f: Single intravenous dose toxicity study in dogs. Daiichi Pharmaceutical Co. Ltd. In house study report (8951J-TOXO19), 1996.
26. ICH Harmonised Tripartite Guidelines for Good Clinical Practice: CPMP/ICH/135/95 which applies to all studies commencing after 17 January, 1997.
27. Declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects, 1989.
28. National Cancer Institute: Guidelines for the Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute 1988.
29. Green S, Weiss G. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-253.
30. Oguma T, Ohshima Y, Nakaoka M. Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection. J Chromatogr B Biomed Sci Appl 2000; 740: 237-245.
31. Rowinsky EK, Johnson TR, Geyer CE Jr et al. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 2000; 18: 3151-3163.
32. Boige V, Raymond E, Faivre S et al. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer. J Clin Oncol 2000; 18: 3986-3992.
33. De Jager R, Cheverton P, Tamanoi K et al. DX-8951f: summary of phase I clinical trials. Ann NY Acad Sci 2000; 922: 260-273.
34. Royce ME, Hoff PM, Dumas P et al. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J Clin Oncol 2001; 19: 1493-1500.
35. O'Reilly S, Rowinsky EK, Slichenmyer W et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996; 14: 3062-3073.